Neurotransmitter interactions in schizophrenia—therapeutic implications

This publication has 25 references indexed in Scilit:

• Functional architecture of basal ganglia circuits: neural substrates of parallel processing
  Published by Elsevier ,2003
• The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1999
• Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
  Proceedings of the National Academy of Sciences, 1997
• Presynaptic dopaminergic function in the striatum of schizophrenic patients
  Schizophrenia Research, 1997
• The selective 5-HT2a receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse ? implications for psychosis
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1995
• Low brain uptake of L‐[¹¹C]5‐hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers
  Acta Psychiatrica Scandinavica, 1991
• Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease
  Trends in Neurosciences, 1990
• Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems
  Pharmacology Biochemistry and Behavior, 1990
• The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1989
• The current status of the dopamine hypothesis of schizophrenia
  Neuropsychopharmacology, 1988